Source:http://linkedlifedata.com/resource/pubmed/id/17071492
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2006-10-30
|
| pubmed:abstractText |
Thirty untreated patients, median age 69 years (range 60 - 75 years), with diffuse large B-cell lymphoma (B-DLCL) were treated with a pegylated liposomal doxorubicin (PL-doxorubicin) modified CHOP-rituximab regimen. PL-doxorubicin 30 mg/m2, was given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses. Cardiac toxicity was evaluated by mean of echocardiography for left ventricular ejection fraction (LVEF) evaluations and serum troponin-I levels. Overall response and complete response rates were 76% and 59%. Projected two year event free survival and overall survival are 65.5% and 68.5%. No treatment-related mortality was documented. WHO grade III-IV neutropenia and thrombocytopenia were 86% and 3%. Extra-hematological III-IV toxicity was represented, respectively, by a single case of infection, mucositis, and bleeding. LVEF evaluations and the troponin levels did not show significant changes over the course of the treatment. One patient with a previous history of atrial fibrillation experienced a single episode of arrhythmia. None of the patients developed palmar-plantar erythrodysesthesia. This regimen appears an active regimen for the treatment of elderly patients with B-DLCL. The replacement of conventional doxorubicin with PL-doxorubicin seems to be associated with a negligible incidence of extra-hematological toxicity, in particular cardiac and infectious complications.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/pegylated liposomal doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1042-8194
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
47
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2174-80
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:17071492-Aged,
pubmed-meshheading:17071492-Antibodies, Monoclonal,
pubmed-meshheading:17071492-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:17071492-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17071492-Cyclophosphamide,
pubmed-meshheading:17071492-Disease-Free Survival,
pubmed-meshheading:17071492-Doxorubicin,
pubmed-meshheading:17071492-Female,
pubmed-meshheading:17071492-Humans,
pubmed-meshheading:17071492-Lymphoma, B-Cell,
pubmed-meshheading:17071492-Male,
pubmed-meshheading:17071492-Middle Aged,
pubmed-meshheading:17071492-Pilot Projects,
pubmed-meshheading:17071492-Polyethylene Glycols,
pubmed-meshheading:17071492-Prednisone,
pubmed-meshheading:17071492-Time Factors,
pubmed-meshheading:17071492-Treatment Outcome,
pubmed-meshheading:17071492-Vincristine
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma.
|
| pubmed:affiliation |
Division of Hematology, DIRM, University Hospital, Udine, Italy. francesco.zaja@med.uniud.it
|
| pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|